Resolvyx, founded in 2005, was a biopharmaceutical company dedicated to the discovery, development, and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. The company ceased operations in 2011.
Latest Press from Resolvyx Pharmaceuticals
- rResolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome 08.24.2009
- Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting 05.07.2009
- Resolvyx Announces Open IND for RX-10045, the Lead Resolvin Therapeutic for Dry Eye 11.20.2008